Linezolid Ratiopharm (Linezolid)

Linezolid blocks bacterial protein synthesis by binding to the 50S ribosomal subunit. This prevents the formation of the initiation complex needed for translation, resulting in a bacteriostatic effect against Gram‑positive organisms, including resistant strains.

The exact dose is determined by the prescribing clinician based on the infection type, severity, and patient characteristics. In adult practice, a common regimen is 600 mg taken twice daily, but the prescriber may adjust the schedule as needed.

Safety data for linezolid in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with vancomycin, linezolid offers oral administration and activity against both MRSA and VRE, whereas vancomycin is given intravenously and lacks efficacy against VRE. Both have distinct safety profiles; linezolid carries risks of thrombocytopenia and serotonin syndrome, while vancomycin is associated with nephrotoxicity and ototoxicity.

Store the product at ambient temperature, below 25 °C, in the original packaging. Protect it from moisture, excessive heat and direct sunlight to maintain stability throughout its shelf life.

Linezolid Ratiopharm is supplied as an oral tablet. The tablet should be swallowed whole with a glass of water and may be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events include thrombocytopenia, peripheral neuropathy, lactic acidosis, and serotonin syndrome, especially when combined with serotonergic drugs. Patients should be monitored regularly for blood‑count changes, neurological symptoms and metabolic disturbances.

Linezolid should be avoided in individuals with known hypersensitivity to linezolid or other oxazolidinones, and in patients currently receiving monoamine oxidase inhibitors. Caution is also advised for those with severe hepatic or renal impairment until safety is confirmed.